In a decision that restores 1,000 hormone replacement therapy mass tort cases to the Philadelphia Common Pleas Court’s caseload, the state Superior Court said it is a question of fact, not a question of law, whether the plaintiffs could have known at the time of their diagnoses with breast cancer that the alleged cause of their cancer was their HRT prescriptions.

The manufacturers of HRT drugs argued that the plaintiffs’ two-year statute of limitations ran from the day they were diagnosed with breast cancer, while the plaintiffs argued that an alleged link between HRT drugs and breast cancer was not known prior to the release of the Women’s Health Initiative study on July 9, 2002. The study received wide-ranging notoriety because the study was discontinued out of the concern that the study participants taking HRT were showing a higher rate of breast cancer than the control group, among other reasons.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]